Detalhe da pesquisa
1.
Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy-A Single-Center Prospective Cohort Study.
Transplant Cell Ther
; 27(9): 788-794, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34214738
2.
Six-month antibody persistence after BNT162b2 mRNA COVID-19 vaccination in patients with chronic lymphocytic leukemia.
Blood Adv
; 6(1): 148-151, 2022 01 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34614513